Unraveling the Mystery: GLP-1 Agonists and Their Impact on Stroke Care
The Potential Game-Changer for Brain Health
At the International Stroke Conference (ISC) 2026, experts delved into the growing evidence surrounding GLP-1 receptor agonists and their potential to revolutionize stroke care. These compounds, initially known for their diabetes treatment and weight loss benefits, are now sparking interest for their anti-inflammatory, vascular, and neuroprotective properties.
Unveiling the Mechanisms
Samarth Shah, PharmD, BCPS, a clinical pharmacy specialist, provided an insightful overview. GLP-1, an endogenous hormone, stimulates insulin secretion and reduces glucagon production in response to glucose. GLP-1 agonists enhance this process by increasing GLP-1's resistance to dipeptidyl peptidase-4, thus extending its half-life. This mechanism has clear benefits for diabetes patients, improving outcomes through insulin stimulation and reduced glucagon levels.
In cardiovascular and cerebrovascular diseases, GLP-1s have shown promise in reducing atherosclerosis, lowering blood pressure through vasodilation, improving lipid profiles, and providing cardiac and renal protection, Shah explained.
The Cerebrovascular Focus
But the key question is how GLP-1 receptor agonists can specifically aid patients with cerebrovascular disease. Shah highlighted the widespread distribution of GLP-1 receptors throughout the nervous system. GLP-1s have demonstrated the ability to inhibit apoptosis and reduce inflammation, which could be crucial in understanding their mechanistic benefits.
In acute ischemic stroke, there might be an increased expression of GLP-1 receptors. Administering GLP-1 agonists post-stroke could theoretically enhance these mechanistic effects as the drug binds to a higher number of receptors.
GLP-1s could potentially protect against cerebral ischemia. The vasodilation associated with GLP-1 agonist use can lead to reduced blood pressure and increased cerebral blood flow, resulting in an increase in cyclic adenosine monophosphate and vascular endothelial growth factor. Additionally, GLP-1s may promote neurogenesis and modulate neurotransmitters, Shah suggested.
The Role in Bolstering Brain Health
Alireza Atri, MD, director of Banner Sun Health Research Institute, built upon this foundation by discussing Alzheimer's disease (AD) and its complex pathophysiology. AD's contribution to neurodegeneration and dementia remains partially understood, but the immune system's significant role in neurodegenerative diseases is evident. Atri emphasized the common occurrence of copathology in brain autopsies of individuals with AD dementia.
The ATX(N) framework updated AD definitions in 2024, separating AD symptoms from the disease itself. Notably, vascular brain injury is included as a biomarker category, defined as infarction on MRI, CT, or white matter hyperintensities. Inflammation, a well-known stroke risk factor, is present throughout the AD disease trajectory.
Research on GLP-1 in neurology dates back to the early 1990s, with studies suggesting a potential role in stroke treatment. A post-hoc analysis of the SUSTAIN 6 and PIONEER 6 studies showed that GLP-1 receptor agonists reduced the incidence of any first stroke with treatment versus placebo in patients with type 2 diabetes and high cardiovascular risk, regardless of prior stroke at baseline. This was primarily attributed to the prevention of small-vessel occlusion.
Leveraging GLP-1 Agonists in Stroke Neurology
In stroke neurology, GLP-1 receptor agonists could play a significant role in prevention. Howard Feldman, a professor of neurosciences, emphasized the evidence supporting GLP-1s in preventing major cardiovascular events, including cardiac issues and strokes. Meta-analyses have been conducted on trials primarily focused on cardiovascular outcomes.
Feldman cited a 2024 meta-analysis published in The International Journal of Stroke, which included 11 cardiovascular outcome trials. The analysis showed that GLP-1s were associated with lower total and nonfatal stroke rates. Additionally, a 2025 publication on secondary stroke prevention with liraglutide versus placebo in participants with type 2 diabetes control demonstrated a 44% lower cumulative incidence of stroke with GLP-1 inhibition versus placebo.
The 2024 Guidelines for the Primary Prevention of Stroke consider GLP-1s effective for type 2 diabetes and weight loss, thereby reducing the risk of stroke and cardiovascular disease. However, there is currently no evidence to suggest that GLP-1 receptor agonists reduce the risk of first-ever stroke when used solely for weight loss without diabetes or high cardiovascular risk.
The potential role of GLP-1s in acute stroke is an area of ongoing exploration. Chris Bladin, MBBS, FRACP, clinical telestroke lead, highlighted the TEXAIS randomized controlled trial on exenatide, which showed positive signals despite an overall negative outcome.
In conclusion, the existing and emerging data suggest a potential role for GLP-1 agonists in stroke care. The exact nature of this role and its impact on future stroke treatment algorithms remain to be determined.
